Recent Posts tagged as 'Drugs'
Blog Post
09/27/2018
By Jonathan A. Havens

The U.S. Drug Enforcement Administration (DEA) is expected to publish in the September 28, 2018 edition of the Federal Register an order scheduling U.S. Food and Drug Administration (FDA or the Agency)-approved drugs that contain cannabidiol (CBD) derived from cannabis and no more than 0.1 percent tetrahydrocannabinols (THC) in Schedule V.

Blog Post
01/22/2018
By Jonathan A. Havens

Within the past few weeks, the U.S. Food and Drug Administration (FDA or the Agency) has, among other things:

Blog Post
07/21/2017
By Jonathan A. Havens

Last week, the U.S. House of Representatives (the House) passed by voice vote the FDA Reauthorization Act of 2017 (FDARA or the Act). Introduced on May 16, 2017 by House Energy and Commerce Committee Chairman Greg Walden (R-Ore.), Ranking Member Frank Pallone (D-NJ), and Health Subcommittee Ranking Member Rep. Gene Green (D-TX), the Act would reauthorize four key U.S.